Tocilizumab Vs Methotrexate in a Cohort of Patients Affected by Active GCA: A Comparative Clinical and Ultrasonographic Study

References

• Mandl P, Limaye V, Adelaide Hospital R, et al. Presentation and Real-World Management of Giant Cell Arteritis (Artemis Study). Frontiers in Medicine. 2021;8.
   Web of Science ®Google Scholar
• Loricera J, Blanco R, Hernández JL, et al. Tocilizumab in giant cell arteritis: multicenter open-label study of 22 patients. Semin Arthritis Rheum. 2015;44(6):717–723. doi:10.1016/j.semarthrit.2014.12.005
   PubMed Web of Science ®Google Scholar
• Régent A, Mouthon L. Treatment of Giant Cell Arteritis (GCA). J Clin Med. 2022;12(1):11. doi:10.3390/jcm12010011
   PubMedGoogle Scholar
• Sebastian A, Kayani A, Prieto-Pena D, et al. Clinical case: efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool. RMD Open. 2020;6(3):e001417. doi:10.1136/rmdopen-2020-001417
   PubMed Web of Science ®Google Scholar
• Nielsen BD, Therkildsen P, Keller KK, Gormsen LC, Hansen IT, Hauge E-M. Ultrasonography in the assessment of disease activity in cranial and large-vessel giant cell arteritis: a prospective follow-up study. Rheumatology. 2023;62(9):3084–3094. doi:10.1093/rheumatology/kead028
   PubMed Web of Science ®Google Scholar
• Conticini E, Sota J, Falsetti P, et al. The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis. Mediators Inflamm. 2020;2020:1–9. doi:10.1155/2020/3203241
   Web of Science ®Google Scholar
• Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122–1128. doi:10.1002/art.1780330810
   PubMed Web of Science ®Google Scholar
• Unizony SH, Dasgupta B, Fisheleva E, et al. Clinical Study Design of the Tocilizumab in Giant Cell Arteritis Trial. Int J Rheumatol. 2013;2013:1–10. doi:10.1155/2013/912562
   Google Scholar
• Ehlers L, Askling J, Bijlsma HWJ, et al. 2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. Ann Rheum Dis. 2019;78(9):1160–1166. doi:10.1136/annrheumdis-2018-214755
   PubMed Web of Science ®Google Scholar
• Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19–30. doi:10.1136/annrheumdis-2019-215672
   PubMed Web of Science ®Google Scholar
• Van Der Geest KSM, Borg F, Kayani A, et al. Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia. Ann Rheum Dis. 2020;79.
   Web of Science ®Google Scholar
• Dejaco C, Ponte C, Monti S, et al. The provisional OMERACT ultrasonography score for giant cell arteritis. Ann Rheum Dis. 2022.
   Web of Science ®Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377(4):317–328. doi:10.1056/NEJMoa1613849
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Isola M, Bruno D, et al. Treatment strategy introducing immunosuppressive drugs with glucocorticoids ab initio or very early in giant cell arteritis: a multicenter retrospective controlled study. J Transl Autoimmun. 2020;3:100072. doi:10.1016/j.jtauto.2020.100072
   PubMedGoogle Scholar
• Conticini E, Falsetti P, Baldi C, Fabiani C, Cantarini L, Frediani B. Routine color Doppler ultrasonography for the early diagnosis of cranial giant cell arteritis relapses. Intern Emerg Med. 2022;17(8):2431–2435. doi:10.1007/s11739-022-03110-w
   PubMed Web of Science ®Google Scholar
• Castañeda S, Prieto-Peña D, Vicente-Rabaneda EF, et al. Advances in the Treatment of Giant Cell Arteritis. J Clin Med. 2022;11(6):1588. doi:10.3390/jcm11061588
   PubMed Web of Science ®Google Scholar
• Sebastian A, Coath F, Innes S, Jackson J, Van Der Geest KSM, Dasgupta B. Role of the halo sign in the assessment of giant cell arteritis: a systematic review and meta-analysis. Rheumatol Adv Pract. 2021;5(3). doi:10.1093/rap/rkab059
   PubMedGoogle Scholar
• Conticini E, Falsetti P, Baldi C, Bardelli M, Cantarini L, Frediani B. Superb microvascular imaging in giant cell arteritis. Clin Exp Rheumatol. 2022;40(4):860–861. doi:10.55563/clinexprheumatol/ygcvaz
   PubMed Web of Science ®Google Scholar
• Ponte C, Monti S, Scirè CA, et al. Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis. Ann Rheum Dis. 2021;80(11):1475–1482. doi:10.1136/annrheumdis-2021-220306
   PubMed Web of Science ®Google Scholar
• Castan P, Dumont A, Deshayes S, et al. Impact of Glucocorticoid Cumulative Doses in a Real-Life Cohort of Patients Affected by Giant Cell Arteritis. J Clin Med. 2022;11(4):1034. doi:10.3390/jcm11041034
   PubMed Web of Science ®Google Scholar
• Albrecht K, Huscher D, Buttgereit F, et al. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. Rheumatol Int. 2018;38(4):569–577. doi:10.1007/s00296-017-3874-3
   PubMed Web of Science ®Google Scholar
• Nannini C, Niccoli L, Sestini S, Laghai I, Coppola A, Cantini F. Remission maintenance after tocilizumab dose-tapering and interruption in patients with giant cell arteritis: an open-label, 18-month, prospective, pilot study. Ann Rheum Dis. 2019;78(10):1444–1446. doi:10.1136/annrheumdis-2019-215585
   PubMed Web of Science ®Google Scholar
• Saito S, Okuyama A, Okada Y, et al. Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study. Rheumatology. 2020;59(7):1617–1621. doi:10.1093/rheumatology/kez511
   PubMed Web of Science ®Google Scholar
• Calderón-Goercke M, Loricera J, Aldasoro V, et al. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. Semin Arthritis Rheum. 2019;49(1):126–135. doi:10.1016/j.semarthrit.2019.01.003
   PubMed Web of Science ®Google Scholar
• Reichenbach S, Adler S, Bonel H, et al. Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis. Rheumatology. 2018;57(6):982–986. doi:10.1093/rheumatology/key015
   PubMed Web of Science ®Google Scholar
• Quinn KA, Grayson PC. The Role of Vascular Imaging to Advance Clinical Care and Research in Large-Vessel Vasculitis. Curr Treatm Opt Rheumatol. 2019;5(1):20–35. doi:10.1007/s40674-019-00114-0
   PubMedGoogle Scholar
• Calderón-Goercke M, Castañeda S, Aldasoro V, et al. Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients. Semin Arthritis Rheum. 2021;51(2):387–394. doi:10.1016/j.semarthrit.2021.01.006
   PubMed Web of Science ®Google Scholar